Literature DB >> 26331605

Statin-Induced Myopathy Is Associated with Mitochondrial Complex III Inhibition.

Tom J J Schirris1, G Herma Renkema2, Tina Ritschel3, Nicol C Voermans4, Albert Bilos5, Baziel G M van Engelen4, Ulrich Brandt6, Werner J H Koopman7, Julien D Beyrath1, Richard J Rodenburg2, Peter H G M Willems7, Jan A M Smeitink8, Frans G M Russel9.   

Abstract

Cholesterol-lowering statins effectively reduce the risk of major cardiovascular events. Myopathy is the most important adverse effect, but its underlying mechanism remains enigmatic. In C2C12 myoblasts, several statin lactones reduced respiratory capacity and appeared to be strong inhibitors of mitochondrial complex III (CIII) activity, up to 84% inhibition. The lactones were in general three times more potent inducers of cytotoxicity than their corresponding acid forms. The Qo binding site of CIII was identified as off-target of the statin lactones. These findings could be confirmed in muscle tissue of patients suffering from statin-induced myopathies, in which CIII enzyme activity was reduced by 18%. Respiratory inhibition in C2C12 myoblasts could be attenuated by convergent electron flow into CIII, restoring respiration up to 89% of control. In conclusion, CIII inhibition was identified as a potential off-target mechanism associated with statin-induced myopathies.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26331605     DOI: 10.1016/j.cmet.2015.08.002

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  66 in total

1.  A benchmark driven guide to binding site comparison: An exhaustive evaluation using tailor-made data sets (ProSPECCTs).

Authors:  Christiane Ehrt; Tobias Brinkjost; Oliver Koch
Journal:  PLoS Comput Biol       Date:  2018-11-08       Impact factor: 4.475

Review 2.  Oxidative stress as a possible mechanism of statin-induced myopathy.

Authors:  Yasin Ahmadi; Amir Ghorbanihaghjo; Mohsen Naghi-Zadeh; Neda Lotfi Yagin
Journal:  Inflammopharmacology       Date:  2018-03-24       Impact factor: 4.473

3.  PGC-1α plays a pivotal role in simvastatin-induced exercise impairment in mice.

Authors:  Miljenko Valentin Panajatovic; François Singh; Noëmi Johanna Roos; Urs Duthaler; Christoph Handschin; Stephan Krähenbühl; Jamal Bouitbir
Journal:  Acta Physiol (Oxf)       Date:  2019-11-04       Impact factor: 6.311

4.  Myopathy in a 61-year-old Hispanic man.

Authors:  Gary Parizher; Timothy J Brown; Mary Hon; Elena K Joerns; Yu Zuo
Journal:  BMJ Case Rep       Date:  2019-04-16

Review 5.  Drug-Induced Mitochondrial Toxicity.

Authors:  Iain P Hargreaves; Mesfer Al Shahrani; Luke Wainwright; Simon J R Heales
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

6.  Cerivastatin Nanoliposome as a Potential Disease Modifying Approach for the Treatment of Pulmonary Arterial Hypertension.

Authors:  Young Lee; S Balakrishna Pai; Ravi V Bellamkonda; David H Thompson; Jaipal Singh
Journal:  J Pharmacol Exp Ther       Date:  2018-04-25       Impact factor: 4.030

Review 7.  Are mechanically sensitive regulators involved in the function and (patho)physiology of cerebral palsy-related contractures?

Authors:  Jessica Pingel; Frank Suhr
Journal:  J Muscle Res Cell Motil       Date:  2017-11-30       Impact factor: 2.698

Review 8.  Exercise-Pharmacology Interactions: Metformin, Statins, and Healthspan.

Authors:  Benjamin F Miller; John P Thyfault
Journal:  Physiology (Bethesda)       Date:  2020-09-01

9.  Muscle rupture associated with statin use.

Authors:  Corine Ekhart; Loek de Jong; Liana Gross-Martirosyan; Florence van Hunsel
Journal:  Br J Clin Pharmacol       Date:  2016-05-18       Impact factor: 4.335

10.  MitoPlex: A targeted multiple reaction monitoring assay for quantification of a curated set of mitochondrial proteins.

Authors:  Aleksandr B Stotland; Weston Spivia; Amanda Orosco; Allen M Andres; Roberta A Gottlieb; Jennifer E Van Eyk; Sarah J Parker
Journal:  J Mol Cell Cardiol       Date:  2020-03-29       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.